Results 181 to 190 of about 231,014 (346)
ABSTRACT Objectives Various drainage methods have been used for unresectable malignant hilar biliary obstruction (MHBO). However, controlling cholangitis and obstructive jaundice is still challenging. We performed a phase I/II study of endoscopic ultrasound‐guided hepaticogastrostomy (EUS‐HGS) as primary drainage for MHBO.
Tomoki Ogata +7 more
wiley +1 more source
Cubebene‐related sesquiterpenes, found across diverse biological sources, exhibit promising pharmacological activities, including anti‐inflammatory, neuroprotective, and anticancer effects. This review highlights their molecular diversity, ADME profiles, and predicted multitarget interactions, underscoring their therapeutic relevance and potential in ...
Khadija Boualam +4 more
wiley +1 more source
Intramuscular fat content and the risk of peritonitis in peritoneal dialysis patients. [PDF]
Xu L +6 more
europepmc +1 more source
ABSTRACT Background Cachexia and sarcopenia are prevalent, inflammation‐linked syndromes in chronic liver disease that worsen outcomes. To our knowledge, their coexistence in a single chronic liver disease cohort has not been systematically examined.
Takatsugu Tanaka +18 more
wiley +1 more source
Unraveling the Enterococcus enigma in ICU peritonitis: a multicenter cohort study. [PDF]
Bardoul M +8 more
europepmc +1 more source
ABSTRACT Knowledge of the potential of biomarkers for monitoring clinical improvement, assessing trajectory or disease progression in advanced chronic liver disease is still insufficient. This study investigated biomarkers of fibrosis and macrophage activation over time in newly diagnosed patients with cirrhosis and their potential association with ...
Emilie Toft Skovgaard +8 more
wiley +1 more source
Sepsis abdominal, peritonitis iterativa - resultados de su manejo
Guillermo J. Pérez +2 more
openalex +2 more sources
A mesocolonic lymphangioma in an adult with peritonitis: a case report [PDF]
Yuzo Hirata +3 more
openalex +1 more source
ABSTRACT While the efficacy of canakinumab, an anti‐interleukin‐1β monoclonal antibody, is well‐established, its safety profile, particularly across different age groups, remains inadequately explored. Using the FDA Adverse Event Reporting System (FAERS) database, this study evaluated postmarketing safety by analyzing adverse event (AE) reports from ...
Youyang Wang +3 more
wiley +1 more source
Nontuberculous Mycobacterium Peritonitis in Patients on Peritoneal Dialysis: A Scoping Review. [PDF]
Tamura H +4 more
europepmc +1 more source

